TARS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

143.78M

+116.52%

-0.110

-81.67%

148.60M

+89.69%

0.033

-105.08%

172.02M

+67.56%

0.390

-181.25%

Estimates Revision

The market is revising Upward the revenue expectations for Tarsus Pharmaceuticals, Inc. (TARS) for FY2025, with the revenue forecasts being adjusted by 0.55% over the past three months. During the same period, the stock price has changed by 9.28%.

Revenue Estimates for FY2025

Revise Upward

+0.55%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.09%

In Past 3 Month

Stock Price

Go Up

+9.28%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast TARS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARS is 80.75 USD with a low forecast of 51.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

51.00

Averages

80.75

High

100.00

Current: 0.000

Low

51.00

Averages

80.75

High

100.00

Barclays

Overweight

initiated

$100

2025-12-08

Reason

Barclays

Price Target

$100

2025-12-08

initiated

Overweight

Reason

Barclays initiated coverage of Tarsus Pharmaceuticals with an Overweight rating and $100 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."

Mizuho

initiated

$100

2025-11-20

Reason

Mizuho

Price Target

$100

2025-11-20

initiated

Reason

Mizuho initiated coverage of Tarsus Pharmaceuticals with an Outperform rating and $100 price target. Tarsus is a commercial stage, ophthalmology-focused company that markets Xdemvy, the only approved treatment for Demodex blepharitis, the analyst tells investors in a research note. The firm projects peak Xdemvy sales in DB of over $2B. Mizuho's physician survey supports the bullish view, it says.

Goldman Sachs

Andrea Tan

Neutral

maintain

$45 -> $51

2025-11-06

Reason

Goldman Sachs

Andrea Tan

Price Target

$45 -> $51

2025-11-06

maintain

Neutral

Reason

Goldman Sachs analyst Andrea Tan raised the firm's price target on Tarsus Pharmaceuticals to $51 from $45 and keeps a Neutral rating on the shares.

H.C. Wainwright

Neutral

maintain

$72 -> $88

2025-10-20

Reason

H.C. Wainwright

Price Target

$72 -> $88

2025-10-20

maintain

Neutral

Reason

H.C. Wainwright raised the firm's price target on Tarsus Pharmaceuticals to $88 from $72 and keeps a Neutral rating on the shares. The firm upped its sales estimates for Xdemvy ahead of the Q3 results based on its conviction in the launch trajectory.

Oppenheimer

Outperform

upgrade

$72 -> $75

2025-06-02

Reason

Oppenheimer

Price Target

$72 -> $75

2025-06-02

upgrade

Outperform

Reason

Oppenheimer assumed coverage of Tarsus Pharmaceuticals with an Outperform rating with a price target of $75, up from $72. The firm notes the company reported Q1 2025 topline of $78.3M, beating consensus estimates, with volume of about 72K surpassing guidance. XDEMVY's momentum remains strong, driven by its growth initiatives. Management highlighted encouraging shifts in prescribing patterns from monthly to weekly prescribing, noting that thousands of target ECPs remain below capacity. Oppenheimer is encouraged by broad commercial, Medicare, and Medicaid coverage. With sales force expansion, coverage, DTC, and evidence generation progressing, plus a strengthened balance sheet, the firm believes XDEMVY's momentum is well-poised to grow.

H.C. Wainwright

Oren Livnat

initiated

$72

2025-05-27

Reason

H.C. Wainwright

Oren Livnat

Price Target

$72

2025-05-27

initiated

Reason

H.C. Wainwright analyst Oren Livnat assumed coverage of Tarsus Pharmaceuticals with a Buy rating and $72 price target. The firm likes the company's Xdemvy impetus in Demodex blepharitis. Xdemvy represents the first and only FDA approved therapy to treat Demodex blepharitis, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Tarsus Pharmaceuticals Inc (TARS.O) is 96.15, compared to its 5-year average forward P/E of 112.45. For a more detailed relative valuation and DCF analysis to assess Tarsus Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

112.45

Current PE

96.15

Overvalued PE

715.35

Undervalued PE

-490.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

5.02

Current EV/EBITDA

69.93

Overvalued EV/EBITDA

48.12

Undervalued EV/EBITDA

-38.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

18.28

Current PS

5.30

Overvalued PS

31.66

Undervalued PS

4.90

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 987.14% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TARS News & Events

Events Timeline

No data

News

9.0

2025-11-19NASDAQ.COM

From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?

9.5

2025-11-05NASDAQ.COM

Tarsus Pharmaceuticals, Inc. (TARS) Posts Q3 Loss but Exceeds Revenue Projections

7.0

2025-11-04SeekingAlpha

Tarsus Sets Q4 Sales Goal of $140M–$145M Amidst Increased XDEMVY Adoption and Pipeline Development

People Also Watch

Frequently Asked Questions

What is Tarsus Pharmaceuticals Inc (TARS) stock price today?

The current price of TARS is 76.87 USD — it has decreased -1.71 % in the last trading day.

What is Tarsus Pharmaceuticals Inc (TARS)'s business?

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

What is the price predicton of TARS Stock?

What is Tarsus Pharmaceuticals Inc (TARS)'s revenue for the last quarter?

Tarsus Pharmaceuticals Inc revenue for the last quarter amounts to 118.70M USD, increased 146.68 % YoY.

What is Tarsus Pharmaceuticals Inc (TARS)'s earnings per share (EPS) for the last quarter?

Tarsus Pharmaceuticals Inc. EPS for the last quarter amounts to -0.30 USD, decreased -50.82 % YoY.

What changes have occurred in the market's expectations for Tarsus Pharmaceuticals Inc (TARS)'s fundamentals?

How many employees does Tarsus Pharmaceuticals Inc (TARS). have?

Tarsus Pharmaceuticals Inc (TARS) has 323 emplpoyees as of January 11 2026.

What is Tarsus Pharmaceuticals Inc (TARS) market cap?

Today TARS has the market capitalization of 3.26B USD.